A Washington University School of Medicine team’s findings might inform future research into inhibitors of angiogenesis and PD-1 in head and neck cancer.
Head and Neck Cancer Targets
AZD1775, a small-molecule, WEE1-targeting TKI, significantly shrunk tumors when administered in combination with cisplatin and docetaxel in a phase I trial.
Selumetinib has received Orphan Drug Designation status by the US Food and Drug Administration to be used as an adjuvant treatment in patients with stage III or IV differentiated thyroid cancer.
Immunotherapy treatment with nivolumab significantly improved survival among patients with recurrent or metastatic head and neck squamous cell carcinoma.
Pembrolizumab demonstrated a 24.8% overall response rate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
The FDA has approved lenvatinib (Lenvima) for the treatment of patients with progressive, differentiated thyroid cancer refractory to radioactive iodine.